DEXLEVO
DEXLEVO, an aesthetic medical device company, attended the international conference on cosmetic formation opening in Paris, IMCAS World Congress 2022 on 2022.06.03~06.05, and introduced the excellence and effectiveness of ‘GOURI’.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005382/en/
IMCAS World Congress is one of the world’s top 3 cosmetic conferences, is an event where over 20,000 visitors from more than 195 countries, including dermatologists, participate every year to share the latest knowledge of the industry.
DEXLEVO held its own symposium at the IMCAS World Congress where they participated for the first time as an Emerald sponsor and demonstrated GOURI treatment techniques. As much as GOURI’s technology and product differentiation was verified by being awarded the Best injectable Collagen Inducer at the AMWC held in Monaco last April, many distributors and doctors attended and gathered attention.
Through the symposium, it was introduced, “The current trend in the cosmetic market is anti-aging, and consumers want natural skin improvement. GOURI satisfies all of the market and consumers’ needs with their natural collagen regenerative effect. Not only that, it is safe compared to competitive products, and the surgical procedure is easy, so the satisfaction level in doctors and patients are both high.”
A DEXLEVO employee said, “We were able to confirm that the awareness of GOURI has increased through this conference. Given that the conference was held at the same level as before Covid-19, I have gained confidence to respond to the demand in the beauty market that will increase after the endemic.
Starting with the launch of GOURI last year, DEXLEVO has been actively discussing contracts with large companies in more than 40 countries including Europe, and in May, it formed a strategic partnership with GS Global to explore global markets. It has signed a distribution and sales contract worth $10 million (about KRW 12.7billion) in Turkey, and plans to expand its market to the EU, MENA, East Asia, and China, including Germany.
After the acquisition of Hugel, GS took its first step into the bio market with DEXLEVO’s ‘GOURI’, which is interpreted as the judgment that GOURI’s technological competitiveness and differentiation can create synergy with its business portfolio. Also, GOURI can be supplemented with botonium toxin, and the expansion of the esthetic distribution network through GOURI is expected to have a synergistic effect when expanding its business portfolio in the future. A GS official said, “The collaboration with DEXLEVO through GOURI is to secure future growth engines for GS Group.”
Meanwhile, it is waiting for approval from the Ministry of Food & Drug Safety (MFDS) after clinical completion in Korea, and is aiming to release products next year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005382/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 18:00:00 CET | Press release
The alliance empowers enterprises with accelerated SDLC cycles, reduced testing effort, and modern AI-driven digital transformation capabilities LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams c
GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 16:11:00 CET | Press release
Acrelec becomes a wholly owned subsidiary of Glory Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and
Andersen Global styrker sin platform i Tyrkiet med tilføjelsen af medlemsvirksomhed26.11.2025 14:49:00 CET | Pressemeddelelse
Andersen Global udvider sin tilstedeværelse i Tyrkiet, efter at Celen Corporate Property Valuation & Counseling Inc. bliver til Andersen i Tyrkiet, hvilket udvider de kompetencer, der tilbydes under Andersen-brandet i landet. Det Istanbul-baserede firma blev stiftet i 1995 og ledes af Managing Partner Guniz Celen med en bred vifte af ydelser til både nationale og internationale kunder. Med ekspertise inden for finansiering af fast ejendom, værdiansættelse af materielle og immaterielle aktiver samt formueforvaltning leverer den tyrkiske afdeling af Andersen løsninger, der understøtter komplekse finansielle beslutninger for kunder i mere end 18 lande. “Vores mission har altid været at levere løsninger på de mest komplekse udfordringer inden for ejendoms- og investeringssektoren,” sagde Guniz. “At blive en del af Andersen-brandet styrker vores kompetencer som en betroet rådgiver og giver os adgang til globale ressourcer, hvilket gør os i stand til at skabe endnu større langsigtet værdi fo
Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 14:00:00 CET | Press release
Transformative combination creates a powerhouse for SMBs and accountants, empowering businesses across Europe by integrating leading suites of e-invoicing, digital accounting, business accounts and payments, and HR solutions into a unified platform. Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, ta
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom